0QND Stock Overview
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0QND from our risk checks.
Bachem Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF84.14 |
52 Week High | CHF105.30 |
52 Week Low | CHF54.70 |
Beta | 0.67 |
1 Month Change | 20.46% |
3 Month Change | 29.43% |
1 Year Change | -6.04% |
3 Year Change | 2.87% |
5 Year Change | 239.51% |
Change since IPO | 705.21% |
Recent News & Updates
Recent updates
Shareholder Returns
0QND | GB Life Sciences | GB Market | |
---|---|---|---|
7D | -0.1% | -5.2% | 2.3% |
1Y | -6.0% | -25.8% | 2.7% |
Return vs Industry: 0QND exceeded the UK Life Sciences industry which returned -23.5% over the past year.
Return vs Market: 0QND underperformed the UK Market which returned 3.7% over the past year.
Price Volatility
0QND volatility | |
---|---|
0QND Average Weekly Movement | 5.5% |
Life Sciences Industry Average Movement | 8.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0QND's share price has been volatile over the past 3 months.
Volatility Over Time: 0QND's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1971 | 2,006 | Thomas Meier | https://www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
0QND fundamental statistics | |
---|---|
Market cap | CHF6.34b |
Earnings (TTM) | CHF111.86m |
Revenue (TTM) | CHF577.32m |
56.7x
P/E Ratio11.0x
P/S RatioIs 0QND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0QND income statement (TTM) | |
---|---|
Revenue | CHF577.32m |
Cost of Revenue | CHF400.35m |
Gross Profit | CHF176.96m |
Other Expenses | CHF65.10m |
Earnings | CHF111.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 1.49 |
Gross Margin | 30.65% |
Net Profit Margin | 19.38% |
Debt/Equity Ratio | 0% |
How did 0QND perform over the long term?
See historical performance and comparison